Acorda Therapeutics Announces Allowance Of Second U.S. Patent Application For AMPYRA Covering Methods Of Use For Improving Walking in Multiple Sclerosis

Acorda Therapeutics announced that the United States Patent and Trademark Office (USPTO) has allowed U.S. Patent Application No. 11/102,559 entitled Method of Using Sustained Release Aminopyridine Compositions. The claims of the patent application relate to methods to improve walking, walking speed, lower extremity muscle tone and lower extremity muscle strength in patients with multiple sclerosis (MS) by administering 10 mg of sustained release 4-aminopyridine (dalfampridine) twice daily. This patent application is separate from the AMPYRA method of use patent application which was allowed by the USPTO in April 2011.